-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novo Nordisk joins hands with Shanghai Pharmaceutical Holdings to promote intelligent drug logistics and warehousing
Novo Nordisk joins hands with Shanghai Pharmaceutical Holdings to promote intelligent drug logistics and warehousingNovo Nordisk and Shanghai Pharmaceutical Holdings Co.
, Ltd.
reached a strategic cooperation
at the 5th CIIE.
Shanghai Pharmaceutical Holdings will provide Novo Nordisk Shanghai with intelligent modern logistics warehouses through innovative pharmaceutical third-party logistics services, and further meet the business development needs
of Novo Nordisk Shanghai in the next ten years with intensive, standardized, informationized and intelligent pharmaceutical logistics management and operations.
Previously, Novo Nordisk has reached a 20-year in-depth cooperation with Shanghai Pharmaceutical Holdings, and this signing is an innovative breakthrough in the tripartite logistics of pharmaceuticals between the two parties, and an important step
for Novo Nordisk to realize the new layout of the whole industry chain of "dual centers and three engines".
The two parties will promote the development of biomedical industry and trade in the Shanghai Lingang New Area to provide better services
to Chinese patients.
Ping An Health has joined hands with Roche and Zhiben Medical to help the precision treatment of pan-cancer species
Ping An Health has joined hands with Roche and Zhiben Medical to help the precision treatment of pan-cancer speciesPing An Health Insurance Co.
, Ltd.
, Shanghai Roche Pharmaceutical Co.
, Ltd.
and Zhiben Medical Technology (Shanghai) Co.
, Ltd.
announced that they have reached strategic cooperation intentions
.
The three parties will jointly expand the service model of innovative payment for pan-solid tumors and solve the actual medication burden
for NTRK-positive patients in China.
NTRK is a rare target for solid tumors and is considered a potential target for anti-tumor precision therapy
.
In July 2022, Roche's pan-cancer drug emtrematinib targeting NTRK was approved in China, bringing innovative therapies
to patients with NTRK-positive solid tumors in China.
At the same time, Zhiben Medical launched China's first Internet hospital NTRK outpatient clinic, which provides pan-cancer NTRK detection technology and NTRK outpatient services to help screen patients suitable for entrectinib
.
In addition, Ping An Health's upcoming insurance products can cover patients' NTRK genetic testing, diagnosis and treatment, and the cost of emtretinib medication
.
Takeda joined hands with the China Medical Insurance Chamber of Commerce to promote the supply of innovative drugs for rare diseases
Takeda joined hands with the China Medical Insurance Chamber of Commerce to promote the supply of innovative drugs for rare diseasesTakeda China and the Chamber of Commerce for Import and Export of Medicines and Health Products (hereinafter referred to as "Medical Insurance Chamber of Commerce") signed a strategic cooperation agreement at the 5th CIIE, the two sides will further strengthen professional cooperation in the field of rare diseases and promote international exchanges
in the field of biomedicine.
Among the 121 rare diseases defined in China, 35 rare diseases face the challenge of having drugs abroad and no drugs in China
.
Takeda has been deeply involved in the field of rare diseases for many years and is committed to providing innovative therapies
for patients with rare diseases.
This cooperation with the China Medical Insurance Chamber of Commerce aims to improve the accessibility of drugs for patients with rare diseases in China, promote the supply of innovative drugs for rare diseases, and promote the continuous improvement
of regulatory policies.
Organon cooperated with Ali Health to jointly explore the innovation of "Internet +" chronic disease management model
Organon cooperated with Ali Health to jointly explore the innovation of "Internet +" chronic disease management modelThe two parties will jointly explore the innovation of "Internet +" chronic disease management model, cooperate in Internet medical treatment, disease management, doctor-patient education and other aspects, create a digital patient management model, and jointly empower online diagnosis and treatment and disease management ecology, so as to improve patient compliance with diagnosis and treatment, help patients achieve more scientific full-cycle management of chronic diseases, and fully enjoy the convenient and efficient one-stop medical services brought by
。
Sanofi will continue to work with CR Sanjiu to accelerate its entry into the Chinese consumer healthcare market
Sanofi will continue to work with CR Sanjiu to accelerate its entry into the Chinese consumer healthcare marketSanofi Consumer Health Pharmaceutical signed a strategic cooperation agreement
with CR Sanjiu during the 5th CIIE.
The cooperation between Sanofi Consumer Health Pharmaceutical and CR Sanjiu began in 2016, and the key cooperation product "Yishanfu" between the two parties has been highly recognized by the industry, occupying the leading share
in the oral liver category.
At this Expo, the two sides renewed the ten-year strategic cooperation agreement
on "Yishanfu".
At the same time, Sanofi released a new sister brand "Yishanli", further improving the liver category product line
.
In addition, Sanofi Consumer Health Pharmaceutical's anti-allergy brand "Allegra" will also officially enter the Chinese anti-allergy market
.
In the future, Sanofi Consumer Health Pharmaceutical will continue to rely on CR Sanjiu's channel and brand advantages to bring better and diversified products
to Chinese consumers.
